ArticleEuropean heart journal. Case reports2026
Utility of a novel point-of-care test in detecting coronary artery disease following negative nuclear testing: a case series.
Article in European heart journal. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Coronary artery disease (CAD) often presents diagnostic challenges, especially in patients with atypical chest pain that persists despite negative non-invasive testing. For instance, nuclear stress testing, although widely used, may yield false-negative results, particularly in cases of balanced ischaemia. Accurate diagnostics are essential to avoid delays in diagnosis and treatment, particularly in the presence of negative nuclear testing. Case summary: We present five cases of intermediate- to high-risk patients with ongoing symptoms (chest pressure/discomfort/pain, nausea, shortness of breath, and exertional fatigue) and negative nuclear stress tests, who were ultimately diagnosed with significant CAD via invasive coronary angiography. In each case, CorVista CAD, a novel point-of-care test for CAD (POC-CAD) that analyses electrical and haemodynamic signals using machine learning, was contributory in raising the probability of disease, prompting invasive evaluation via coronary angiography and guiding appropriate management strategies. Discussion: This case series demonstrates the utility of POC-CAD as a non-invasive tool in the diagnostic pathway for patients with ongoing symptoms despite negative nuclear stress testing. The findings highlight limitations of nuclear stress testing, particularly its reduced sensitivity in multi-vessel disease. POC-CAD may help identify high-risk patients who would otherwise be missed, facilitating timely intervention. Integration of novel diagnostics such as POC-CAD into multimodal assessment strategies could improve accuracy and reduce diagnostic delays in CAD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.